Kaitlyn D’Onofrio

DocwireNews

A new study examined the cost-benefit of <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/interview-defactinib-plus-pembrolizumab-and-gemcitabine-effective-in-pancreatic-cancer-patients/">cancer</a> drugs and found no correlation between the two.&ldquo;Our study clearly shows that, in general, for Switzerland, Germany, England and the United States, there is no association between clinical benefit of a cancer drugs and their prices,&rdquo; lead study author Kerstin Vokinger, MD, explained <a href="https://www.eurekalert.org/pub_releases/2020-04/uoz-hco043020.php">in a press release</a>. &ldquo;It&rsquo;s also clear that the prices of cancer drugs in the US are significantly higher than in the four European countries, with Americans paying on average approximately twice as much for the same drug.&rdquo;To conduct their study, the researchers investigated all new drugs with initial indications for adult cancers given U.S. Food and Drug Administration approval between Jan. 1, 2009, and Dec. 31, 2017; for the European Medicines Agency, approvals through Sept. 1, 2019, were examined. They used the American Society of Clinical Oncology-Value Framework (ASCO-VF) and European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) to analyze drugs indicated for solid tumors, comparing monthly drug treatment <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/heres-how-out-of-pocket-spending-for-ra-biologic-drugs-was-affected-by-medicare-part-d/">costs</a> between benefit levels with hierarchical linear regression models. The Spearman&rsquo;s correlation coefficients were calculated between costs and benefit levels for the U.S., England, Switzerland, Germany, and France.Final analysis included 65 drugs, most of which (n=47, 72%) were approved for solid tumors; 18 (28%) were approved for hematological malignancies. Monthly drug treatments cost a median 2.31 times more in the U.S. compared to the European countries. Monthly treatment costs for solid tumors were not correlated with clinical benefit in all five countries when using the ESMO-MCBS (P=0.16 for the U.S., P=0.98 for England, P=0.54 for Switzerland, P=0.52 for Germany, and P=0.40 for France); the same was true when using the ASCO-VF, except for France (P=0.56 for the U.S., P=0.47 for England, P=0.26 for Switzerland, P=0.23 for Germany, and P=0.037 for France).The study was published in <a href="https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(20)30139-X.pdf">The Lancet Oncology</a>.Dr. Vokinger, a professor at the University of Zurich, said, &ldquo;The pricing of cancer drugs is only partially justified. Drugs that are less effective should be cheaper than those with high efficacy.&rdquo;She added, &ldquo;National authorities should take greater account of the clinical benefits of drugs when negotiating prices, and therapies that provide high clinical benefit should be prioritized in price negotiations.&rdquo;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Cost of Cancer Drugs Does Not Always Align with Clinical Benefit

Oncology

A new study examined the cost-benefit of cancer drugs and found no correlation between the two. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe